# Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

> **NCT04025632** · PHASE2 · TERMINATED · sponsor: **Ra Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Immune Mediated Necrotizing Myopathy

## Interventions

- **DRUG:** zilucoplan
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04025632
- **Lead sponsor:** Ra Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-07
- **Primary completion:** 2021-03-04
- **Final completion:** 2021-06-14
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** The study was terminated based on the primary efficacy endpoint analysis after the first data lock.
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04025632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04025632, "Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04025632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*